These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 9718944

  • 1. [Chronic myeloproliferative diseases].
    Sréter L.
    Orv Hetil; 1998 Jul 26; 139(30):1779-83. PubMed ID: 9718944
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan 26; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 5. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
    Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G, Engström-Laurent A.
    Med Oncol; 2007 Jan 26; 24(1):63-70. PubMed ID: 17673813
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New drugs in essential thrombocythemia and polycythemia vera.
    Tefferi A, Elliott MA, Solberg LA, Silverstein MN.
    Blood Rev; 1997 Mar 26; 11(1):1-7. PubMed ID: 9218101
    [Abstract] [Full Text] [Related]

  • 8. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R, Marzetta K, Miglioranza A, Redaelli S, Maino C, Maffiolini A, Gorini M.
    Recenti Prog Med; 2003 Mar 26; 94(7-8):314-20. PubMed ID: 12868237
    [Abstract] [Full Text] [Related]

  • 9. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP, Sanchez SR, Ewton AA, Rice L, Perkins SL, Dunphy CH, Chang CC.
    Hum Pathol; 2008 Oct 26; 39(10):1454-8. PubMed ID: 18619646
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS.
    Oncology (Williston Park); 2001 Aug 26; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [Abstract] [Full Text] [Related]

  • 11. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT, Kiladjian JJ, Hasselbalch HC.
    Expert Rev Hematol; 2013 Feb 26; 6(1):49-58. PubMed ID: 23373780
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Chronic myeloproliferative disorders. The new WHO classification].
    Thiele J, Kvasnicka HM.
    Pathologe; 2001 Nov 26; 22(6):429-43. PubMed ID: 11766643
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R.
    Leuk Res; 2017 Mar 26; 54():73-77. PubMed ID: 28113109
    [Abstract] [Full Text] [Related]

  • 17. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 18. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 06; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 19. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP.
    N Engl J Med; 1988 May 19; 318(20):1292-4. PubMed ID: 3362187
    [Abstract] [Full Text] [Related]

  • 20. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
    Antelo ML, de Las Heras N, Gonzalez Porras JR, Kerguelen A, Raya JM.
    Expert Rev Hematol; 2015 Dec 19; 8(6):819-35. PubMed ID: 26368319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.